1 / 44

Assessment & Management of Chronic Non-Malignant Pain

Assessment & Management of Chronic Non-Malignant Pain. Randy Brown, M.D. Assistant Professor UW Dept of Family Medicine PhD Candidate UW Dept of Population Health Sciences 6/8/06. Chronic Nonmalignant Pain (CNMP). Present ≥ 3 mos. Nociceptive, neuropathic, or mixed

moswen
Download Presentation

Assessment & Management of Chronic Non-Malignant Pain

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Assessment & Management of Chronic Non-Malignant Pain Randy Brown, M.D. Assistant Professor UW Dept of Family Medicine PhD Candidate UW Dept of Population Health Sciences 6/8/06

  2. Chronic Nonmalignant Pain (CNMP) • Present ≥ 3 mos. • Nociceptive, neuropathic, or mixed • Continuous often w/ intermittent flare • Negative impact upon • Well-being • Level of function • Quality of life

  3. CNMP Epidemiology • Pain = most common presenting complaint • 50 million Americans • ~8% have diffuse musculoskeletal pain

  4. Common Diagnoses • Osteoarthritis • Rheumatoid arthritis • Spinal arthropathies/disc disease +/- radiculopathy • Complex regional pain (reflex sympathetic dystrophy) • Fibromyalgia • Myofascial pain • Painful peripheral neuropathies • Post-herpetic neuralgia • HIV disease • Headache syndromes

  5. CNMP Challenges • Little appropriate prospective data • Pain complaints often >> findings • Psychiatric comorbidity common • Concerns re: long-term opioids • Decrease patient function? • Unmanageable adverse effects? • Increase pain? • Cause addiction? • The State Medical Board and DEA are watching. . .

  6. Main Points • Appropriate assessment includes pain, medical, psychiatric, and substance use history • Care = multi-disciplinary • Negotiate individualized, quantifiable treatment goals • Watch the 4 A’s • Analgesia • Activity • Adherence • Adverse effects

  7. “Drug-Host Interaction” Initial Visit: Assessment • Pain complaint history • Functional impact • Medical co-morbidity • Psychiatric history • Substance use history

  8. severe mod. mild 0 1 3 4 6 7 10 No pain Worst pain Initial Visit: Assessment • Pain complaint • Onset/chronology • Characterization • Quality • Location/referral/radiation • Intensity • Visual Analog Scale

  9. Initial Visit: Assessment • Pain complaint • Onset/chronology • Characterization • Quality • Location/referral/radiation • Intensity • Aggravating/alleviating factors • Additional symptoms • Functional impact • Work • Activities of Daily Living • Sleep • Mood • Social

  10. Initial Visit: Assessment • Treatment history • Surgical/interventional • Pharmacotherapeutic • Rehabilitation/physiatry • Psychiatric • Complementary

  11. Initial Visit: Exam • Musculoskeletal • Neurological • Screening for anxiety/depression • Functional assessment • Lab/radiography—if indicated

  12. Initial Visit: Treatment Goals • Goals/expectations = negotiated, realistic, measurable • Realms to consider: • Pain relief • Function • Sleep • Coping skills • Affective distress • Work/vocational retraining

  13. Treatment Components • Physical rehabilitation • Function • Pain control • Self-management • Psychological/behavioral • Interventional/surgical • Complementary • Pharmacotherapy

  14. Treatment: Pharmacotherapy • NSAIDs • Indication: mild-mod pain • Nociceptive > neuropathic • Adverse effects (fx): GI, renal, hypertension • Acetaminophen • Indication: mild-mod pain • Dosing < 4g daily • Adverse fx: hepatotoxicity, renal insufficiency

  15. Treatment: Pharmacotherapy • Adjunctive Rx • Topicals (e.g. capsaicin) • Anticonvulsants (e.g. Tegretol, Neurontin) • Tricyclic antidepressants • Selective serotonin reuptake inhibitors (FMR, IBS) • “Muscle relaxants”

  16. Treatment: Pharmacotherapy • Opioids • Indications • Mod-severe pain • Functional impact • Failure of non-opioids • Primary agent = long-acting if used daily • ↓ withdrawal, euphoria, abuse/dependence • ↑ pain control, tolerance to adverse fx “Drug-Host Interaction”

  17. Serum level 8PM 8AM Noon 4PM MN 4AM 8AM Long- vs. Short-Acting Opioids Adverse Effects Therapeutic Window Ineffective/opioid withdrawal

  18. Serum level 8PM 8AM Noon 4PM MN 4AM 8AM Long- vs. Short-Acting Opioids

  19. Opioid Dose Titration • Opioid naïve • Scheduled + as needed short-acting preparation • When dose stable, convert to long-acting dose equivalent • http://globalrph.com/narcoticonv.htm • http://www.globalrph.com/narcotic_pda.htm • Reduce dose-equivalent by 25-50% if converting to a different opioid • Non-naïve  2 and 3 above

  20. “Special” Opioids • Codeine • Tramadol • Meperidine • Propoxyphene • Mixed agonist/antagonists (butorphanol) • Methadone

  21. Tolerance develops Long-Term Opioid Adverse Effects • No known end-organ toxicity • Sedation • Nausea • Pruritis

  22. Long-Term Opioid Adverse Effects • Constipation • Myoclonus • Hypogonadism • Pain facilitation (hyperalgesia) • Abuse/dependence

  23. Constipation • Bowel regimen • ↑ fluids/fiber • Encourage mobility • Stool softener (ducosate) +/- stimulant laxative (senna)

  24. Somnolence/Sedation • Reduce dose if analgesia adequate • Consider addition of stimulant (modafinil)

  25. Myoclonus • Reduce dose • Rotate opioids • Benzodiazepine = last resort

  26. Hypogonadism • Women • Dose ↓ • Opioid rotation • Oral contraceptive • Men • Topical or intramuscular testosterone

  27. Pain Facilitation/Hyperalgesia • If ↑↑ ing dose w/o ↑ pain relief: • Reconsider Dx/progression of disease • Rotate opioids • Taper or discontinuation • 15-25% Q 3-5 days • Slow during last ½

  28. Opioid Abuse • 1+ in 12 month period due to use: • Failure to fulfill major obligations (work, school, home) • Recurrent use in hazardous situations • Recurrent legal consequences • Continued use despite recurrent/persistent interpersonal problems • Not dependence

  29. Physical dependence ≠ opioid dependence/addiction Opioid Dependence • 3+ in 12 months: • Tolerance • Withdrawal • Larger amounts/longer periods than intended • Persistent desire/failed attempts to quit or ↓ use • Much time obtaining, using, or recovering • Important activities sacrificed • Use continues despite knowledge of adverse effects

  30. Pseudoaddiction • Aberrant behaviors surrounding opioids due to inadequately controlled pain NOT abuse/dependence

  31. Opioid Use Disorder + CNMP • AODA consultation (diagnose/treat) • Treatment program • Methadone treatment facility • Buprenorphine • Detox/taper • Opioid analgesic taper • Clonidine + adjuncts • Consider inpatient

  32. Treatment fx/risk Abuse/dep criteria Monitoring Opioid Recipients Analgesia Activity Adverse Effects Adherence

  33. Activity • Bed days in last 30 • Missed work/school • Failed social obligations • Tolerance of walking, lifting, household chores, hobbies etc.

  34. Adverse Effects: Use Disorders • Red Flag: overt focus on obtaining opioids despite adverse fx, ineffective analgesia, and/or ↓ function

  35. Adherence • Attending visits not related to opioids? • Loss of control over opioid use? • Took opioids for pain or for craving? • Took opioids for indication other than pain (anxiety, stress, depression, or non-restorative sleep)?

  36. Addicted patient Out of control of meds Meds decrease QOL Wants med increase despite side f/x In denial re: medical problems Does not follow treatment plan Pain patient Not out of control of meds Meds improve QOL Aware of side f/x Appropriate concern about medical problems Follows agreed upon treatment plan Adherence: CNMP vs. SUD

  37. Adherence: Concerning Behaviors • Out of town patient • Cash-paying patient • “No” becomes “yes” • Telephone requests for narcotics • Multiple allergies (NSAIDs, codeine. . .) • Frequent no-shows

  38. Adherence: Concerning Behaviors • Overly focused on medication rather than pain relief • Multiple Rx “losses” • Functional deterioration • Repeated resistance to changes in Rx despite clear evidence of adverse fx or lack of efficacy

  39. Pseudoaddiction vs. SUD • Name-brand requests (?) • Aggressive complaining about need for ↑ analgesia • Drug hoarding when ↓ symptoms • Openly acquiring narcotics from other medical sources • Unsanctioned dose ↑

  40. Adherence: Pain Management Agreements • One prescriber/one pharmacy • Prescriptions must last as intended • No after-hours refill requests • Lost prescriptions not replaced • Safe activities when drowsy • Additional required care • Random urine drug screens • Possible responses to violations

  41. Urine Drug Screens • Detects other substance use NOTabuse/dependence • MAY aid in detecting diversion • need to specifically order prescribed opioid testing • consider urine dip for pH, SG, plus urine Cr & temp. • results should be discussed with patient

  42. Regulatory Issues • DEA concerned with intentional diversion • State Medical Boards most often involved in MD discipline • Complaint driven

  43. Regulatory Issues • Document!! • Pain assessment/diagnosis • Function • Subst. use/Ψ hx • Exam/diagnostic testing • Follow-up (4 A’s) • Tx goals/pain mgmt agreement • Reassess pain/substance use in setting of agreement violations

  44. Summary • Appropriately assess pain & co-morbidity • CNMP care = multidisciplinary • Establish realistic goals you can measure • Watch and document 4 A’s

More Related